» Articles » PMID: 37726794

Cell-free Therapy Based on Extracellular Vesicles: a Promising Therapeutic Strategy for Peripheral Nerve Injury

Overview
Publisher Biomed Central
Date 2023 Sep 19
PMID 37726794
Authors
Affiliations
Soon will be listed here.
Abstract

Peripheral nerve injury (PNI) is one of the public health concerns that can result in a loss of sensory or motor function in the areas in which injured and non-injured nerves come together. Up until now, there has been no optimized therapy for complete nerve regeneration after PNI. Exosome-based therapies are an emerging and effective therapeutic strategy for promoting nerve regeneration and functional recovery. Exosomes, as natural extracellular vesicles, contain bioactive molecules for intracellular communications and nervous tissue function, which could overcome the challenges of cell-based therapies. Furthermore, the bioactivity and ability of exosomes to deliver various types of agents, such as proteins and microRNA, have made exosomes a potential approach for neurotherapeutics. However, the type of cell origin, dosage, and targeted delivery of exosomes still pose challenges for the clinical translation of exosome therapeutics. In this review, we have focused on Schwann cell and mesenchymal stem cell (MSC)-derived exosomes in nerve tissue regeneration. Also, we expressed the current understanding of MSC-derived exosomes related to nerve regeneration and provided insights for developing a cell-free MSC therapeutic strategy for nerve injury.

Citing Articles

Potentially commercializable nerve guidance conduits for peripheral nerve injury: Past, present, and future.

Liu C, Sun M, Lin L, Luo Y, Peng L, Zhang J Mater Today Bio. 2025; 31:101503.

PMID: 40018056 PMC: 11867546. DOI: 10.1016/j.mtbio.2025.101503.


CD9-enriched extracellular vesicles from chemically reprogrammed basal progenitors of salivary glands mitigate salivary gland fibrosis.

Park S, Yoon Y, Hong Y, Yu J, Cho J, Jeong Y Bioact Mater. 2025; 47:229-247.

PMID: 39925710 PMC: 11803853. DOI: 10.1016/j.bioactmat.2025.01.019.


Erythropoietin decreases apoptosis and promotes Schwann cell repair and phagocytosis following nerve crush injury in mice.

Govindappa P, Ellur G, Hegarty J, Gupta A, Rahul V, Elfar J bioRxiv. 2025; .

PMID: 39896684 PMC: 11785138. DOI: 10.1101/2025.01.22.634402.


Bridging bioengineering and nanotechnology: Bone marrow derived mesenchymal stem cell-exosome solutions for peripheral nerve injury.

Chang J, Yin X, Zhang M, Liu J, Zhao L World J Stem Cells. 2025; 17(1):101161.

PMID: 39866899 PMC: 11752453. DOI: 10.4252/wjsc.v17.i1.101161.


Treatment for peripheral nerve injury: a protocol for a systematic review and Bayesian network meta-analysis.

Yang Y, Gu W, Xu S, Wang S, Shi H, Zhang L BMJ Open. 2024; 14(12):e090497.

PMID: 39732487 PMC: 11683916. DOI: 10.1136/bmjopen-2024-090497.


References
1.
DAgnelli S, Gerra M, Bignami E, Arendt-Nielsen L . Exosomes as a new pain biomarker opportunity. Mol Pain. 2020; 16:1744806920957800. PMC: 7493250. DOI: 10.1177/1744806920957800. View

2.
Lovati A, DArrigo D, Odella S, Tos P, Geuna S, Raimondo S . Nerve Repair Using Decellularized Nerve Grafts in Rat Models. A Review of the Literature. Front Cell Neurosci. 2018; 12:427. PMC: 6254089. DOI: 10.3389/fncel.2018.00427. View

3.
Lu L, Dong J, Liu Y, Qian Y, Zhang G, Zhou W . New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer. Front Pharmacol. 2022; 13:964793. PMC: 9420899. DOI: 10.3389/fphar.2022.964793. View

4.
Muangsanit P, Shipley R, Phillips J . Vascularization Strategies for Peripheral Nerve Tissue Engineering. Anat Rec (Hoboken). 2018; 301(10):1657-1667. PMC: 6282999. DOI: 10.1002/ar.23919. View

5.
Wang Y, Zhai W, Zhang H, Cheng S, Li J . Injectable Polyzwitterionic Lubricant for Complete Prevention of Cardiac Adhesion. Macromol Biosci. 2023; 23(4):e2200554. DOI: 10.1002/mabi.202200554. View